Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects

Completed · Phase 1

Conditions studied: Healthy

In brief

This study is an open-label, single-dose, parallel group study to evaluate the effects of age and gender on the pharmacokinetics, safety, and tolerability of HCV-796 administered orally to healthy subjects.

Key facts

Study ID

NCT00407173

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

48

Starts

2006-11-01

Expected to finish

2007-06-01

Last updated by the study team

2008-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• Study site — Gainesville, Florida, United States
• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.